ZELBORAF (vemurafenib) - Risk of progression of certain types of cancer and risk of serious rash

Hoffmann-La Roche Limited (Roche Canada), in collaboration with Health Canada, would like to inform you of important new safety information associated with ZELBORAF regarding the risk of malignancy progression as well as the risk of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS Syndrome). ZELBORAF is indicated as a monotherapy for the treatment of proto-oncogene serine/threonine-protein kinase B-Raf V600 mutation-positive unresectable or metastatic melanoma. Read more here.